Elaine Blais, partner and head of the litigation department in Goodwin’s Boston office, discusses whether the US patent system is likely to see reform in the near future with The Center for Biosimilars. Watch the video here.
Related Content
- Big Molecule WatchMay 1, 2024
PTAB Issues Final Written Decisions Finding Claims of Recombinant Lentiviral Vector Patents Valid
- Life Sciences PerspectivesApril 30, 2024
FDA Issues Final Rule on Regulation of Laboratory Developed Tests
- Big Molecule WatchApril 30, 2024
Biosimilar Approval Updates in Europe and China
- Big Molecule WatchApril 29, 2024
GSK Sues Pfizer, Pharmacia & Upjohn & BioNTech for Infringing mRNA Vaccine Patents
- Big Molecule WatchApril 29, 2024
Moderna Litigation Against BioNTech and Pfizer Stayed Pending IPR
- Big Molecule WatchApril 26, 2024
Alvotech Announces Positive Topline Results From Confirmatory Clinical Study for its Proposed Golimumab Biosimilar
- AlertApril 25, 2024
FTC Issues Final Rule Prohibiting Most Post-Employment Non-Compete Agreements
- Life Sciences PerspectivesApril 23, 2024
The European Parliament Adopts Position on the European Commission’s Proposal for the First Major Overhaul of the EU Medicines Regulatory Framework in 20 Years
- Press ReleaseApril 29, 2024
Deciphera Pharmaceuticals To Be Acquired By ONO Pharmaceutical For $2.4 Billion
- Press Release29 April 2024
Amid Continued Growth in the United Kingdom, Goodwin Relocates London Office to Iconic Paternoster Square
- Press ReleaseApril 23, 2024
Allurion Technologies Completes $48 Million Convertible Senior Secured Note Financing with RTW Investments
- Press ReleaseApril 22, 2024
Sound Bioventures joins £19 Million Financing of Theolytics
- In the PressApril 22, 2024
PowerUp 4 - Omer Tene (Spotify)
- Awards and RankingsApril 18, 2024
Goodwin is Number One in the Q1 2024 League Table Rankings
- Press ReleaseApril 18, 2024
Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval
- Press ReleaseApril 17, 2024
Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma